ArticleFrontiers in pediatrics2026
Homocysteine is a risk factor for reduced ejection fraction in children with myocarditis: a single-center study.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between homocysteine (HCY) and ejection fraction (EF) has been demonstrated in diseases such as coronary artery disease, but the relationship between HCY and EF in pediatric patients with myocarditis remains unclear. The aim of this study was to investigate the relationship between HCY and EF in pediatric patients with myocarditis. Methods: This single-center cross-sectional study included 164 pediatric myocarditis patients aged 1-18 years, including 104 males and 60 females, at Anzhen Hospital (2023-2024) in Beijing. Patient demographic characteristics were collected, and blood tests were performed to assess HCY, routine blood tests, and markers of myocardial damage. EF was measured using 3.0T cardiac magnetic resonance (CMR), and patients were grouped using EF < 55% as the cutoff value. Statistical analyses were performed using t-tests, Binary logistic regression and Restrict cubic spline (RCS), and subgroup analyses [age, sex, body mass index (BMI)]. Results: Of the 164 patients, 31% ( Conclusion: The findings suggest that elevated HCY levels are a risk factor for EF < 55% in pediatric patients with myocarditis, especially in males and overweight individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.